Danaher Corporation (DHR)vsIQVIA Holdings Inc (IQV)
DHR
Danaher Corporation
$184.30
-0.33%
HEALTHCARE · Cap: $128.18B
IQV
IQVIA Holdings Inc
$183.45
-1.84%
HEALTHCARE · Cap: $30.29B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 49% more annual revenue ($24.78B vs $16.63B). DHR leads profitability with a 14.9% profit margin vs 8.3%. IQV appears more attractively valued with a PEG of 0.73. IQV earns a higher WallStSmart Score of 66/100 (B-).
DHR
Buy58
out of 100
Grade: C
IQV
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-58.2%
Fair Value
$114.63
Current Price
$184.30
$69.67 premium
Margin of Safety
+9.1%
Fair Value
$194.83
Current Price
$183.45
$11.38 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Generating 1.1B in free cash flow
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
Premium valuation, high expectations priced in
3.7% revenue growth
ROE of 7.0% — below average capital efficiency
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.73 suggests the stock is reasonably priced for its growth.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.
Bear Case : IQV
The primary concerns for IQV are Piotroski F-Score, Altman Z-Score.
Key Dynamics to Monitor
IQV carries more volatility with a beta of 1.22 — expect wider price swings.
IQV is growing revenue faster at 8.4% — sustainability is the question.
DHR generates stronger free cash flow (1.1B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
IQV scores higher overall (66/100 vs 58/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?